A phase III trial has shown that patients whose lung cancer has developed resistance to the drug gefitinib experience no statistically significant improvement in progression-free survival from continued treatment with the drug in addition to chemotherapy. The IMPRESS trial presented at the ESMO 2014 Congress is a randomised phase III study that compared continuation of gefitinib in addition to chemotherapy against chemotherapy alone in patients with lung cancer ...You have just read an article categorized health
titled Continuing Tyrosine Kinase Inhibitor Therapy After Resistance Development in Lung Cancer.
Written by:
editor - Monday, September 29, 2014
There are currently no comments for "Continuing Tyrosine Kinase Inhibitor Therapy After Resistance Development in Lung Cancer"
Post a Comment